免疫|痒，挠，痒。。。要想搞定折磨全球数亿人的特应性皮炎，需要从单点突破到直指核心丨奇点深度( 三 ) 核心|炎症|疾病|粒细胞|折磨

特应性皮炎长期控制很难，约有6成中重度特应性皮炎成人患者，即使已经接受治疗，病情依旧得不到满意的缓解[20] 。毫无疑问，度普利尤单抗的出现带来了新的希望。
从临床试验结果看，度普利尤单抗能够快速、强效、持续改善特应性皮炎患者的瘙痒、消除皮损等症状。治疗开始2天后，即可观察到瘙痒的显著改善；治疗开始第52周， 8成患者EASI评分较基线显著改善，且生活质量实现有临床意义的改善[21] 。度普利尤单抗进入医保后，有更多患者使用到了创新的生物制剂，也给出了很好的临床反馈。
未来，以2型炎症为靶向的治疗方法会进一步拓展到其他2型炎症性疾病，想必一定能够为久受疾病之苦的患者带来新生。
编辑神叨叨
奇点又上新啦！！！
这次的课程，我们用10讲系统梳理了晚期肺癌治疗20年的风云变幻。细致盘点了靶向治疗的最新进展，也全面展现了罕见靶点研究的勃勃生机。当然免疫治疗也是重中之重，我们会带你再次洞察免疫治疗的深层机制，深入免疫治疗最前线，探讨迈入无化疗时代的治疗选择，一起见证辅助和新辅助治疗开疆拓土的战绩。除此之外，我们还会和你一起凝视纷繁复杂的生物标志物研究，探究免疫治疗新靶点的无限潜力。
当然，深度不意味着晦涩，复杂不等同于繁复。我们竭尽全力将这些庞杂的知识点融汇成精湛的音频课程，让你听得轻松、顺畅，不头大，让这些知识快速整合到我们的认知体系，成为下一步进阶的土壤。
说了半天，这么好的课程，原价只需39.9元，认证购买仅需9.9元，也就半杯奶茶的钱！既然看到这里了，就立刻扫描下方二维码，购买收听起来吧！
参考资料：
[1] Asher, M. I. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic
rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry crosssectional surveys. Lancet 368, 733–743 (2006).
[2] Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
[3] Prescott, S. L. et al. A global survey of changing patterns of food allergy burden in children.
World Allergy Organ. J. 6, 21 (2013).
[4] Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity[J]. Journal of Allergy and Clinical Immunology, 2015, 135(3): 626-635.
[5] Lloyd C M, Snelgrove R J. Type 2 immunity: Expanding our view[J]. Science immunology, 2018, 3(25).
[6]https://www.sanofi.com/en/science-and-innovation/stories/taking-down-type-2-inflammatory-disease
[7] Gandhi N A, Bennett B L, Graham N M H, et al. Targeting key proximal drivers of type 2 inflammation in disease[J]. Nature reviews Drug discovery, 2016, 15(1): 35-50.
[8] Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. The Lancet, 2019, 394(10196): 407-418.
[9] Cheng L, Chen J, Fu Q, et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis[J]. Allergy, asthma & immunology research, 2018, 10(4): 300.
[10] Dellon E S, Hirano I. Epidemiology and natural history of eosinophilic esophagitis[J]. Gastroenterology, 2018, 154(2): 319-332. e3.
[11] Ravid N L, Annunziato R A, Ambrose M A, et al. Mental health and quality-of-life concerns related to the burden of food allergy[J]. Immunology and Allergy Clinics, 2012, 32(1): 83-95.
[12] Weidinger S, Beck L A, Bieber T, et al. Atopic dermatitis[J]. Nature Reviews Disease Primers, 2018, 4(1): 1.
[13] C. Philpott, S. Erskine and C. Hopkins, “Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study,” Respiratory Research, vol. 19, p. 129, 2018.